表紙
市場調查報告書
商品編碼
1040460

非小細胞肺癌的全球市場(2021年∼2027年)

Non-Small Cell Lung Cancer Market 2021-2027

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球非小細胞肺癌的市場規模在預測期間內預計將以9.6%大幅年複合成長率成長。帶動這個市場的主要原因有對與採用先進療法相關的研究的興趣增加以及與癌症疾病相關的患病率增加等。

在 COVID-19 大流行期間,市場低迷,因為大多數經濟活動在 2020 年第一和第二季度停止。此外,COVID-19 大流行中斷了醫院就診和與患者治療相關的時間表,導致治療延誤。

本報告提供全球非小細胞肺癌市場調查,提供市場概要,市場的推動因素與阻礙因素分析,COVID-19的影響,市場機會,類型·治療方法·診斷·終端用戶·各地區的市場分析,主要企業的簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的開發
  • 主要策略分析
  • COVID-19對主要企業的影響

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 非小細胞肺癌的全球市場:各類型
    • 腺癌症
    • 扁平表皮癌症
    • 肺大細胞癌症
    • 其他
  • 非小細胞肺癌的全球市場:不同治療
    • 化療
    • 標靶治療
    • 放射治療
    • 手術
    • 冷凍治療
    • 其他
  • 非小細胞肺癌的全球市場:各診斷
    • 電腦斷層掃描
    • X光
    • 痰液細胞學檢查
    • 支氣管鏡檢驗
    • 實驗室實驗
    • 胸腔鏡子檢驗
    • 其他
  • 非小細胞肺癌的全球市場:各終端用戶
    • 多專門科醫院
    • 癌症調查中心

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • AbbVie Inc.
  • Agena Bioscience, Inc.
  • Arqule Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biodesix, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • DAIICHI SANKYO CO. LTD.
  • Eli Lilly and Co.
  • Exosome Diagnostics Corp.
  • F. Hoffman-La Roche, Inc.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Merck & Co., Inc.
  • Novartis International Ag
  • Personal Genome Diagnostics Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi SA
  • SAGA Diagnostics AB
  • Thermo Fisher Scientific Inc.
目錄
Product Code: OMR2024011

Global Non-Small Cell Lung Cancer Market Size, Share &Trends Analysis Report By Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others), By Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Cryosurgery, and Others), By Diagnosis (CT scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), and By End-User (Multispecialty Hospitals and Cancer Research Centers) Forecast Period, 2021-2027

The global non-small cell lung cancer market is anticipated to grow at a substantial CAGR of 9.6% during the forecast period. The market is set to display impressive growth during the forecast period with some key trends emerging, such as the growing focus on research related to advanced therapies adoption and rising incidences associated with cancer disease

The global non-small cell lung cancer market suffered a downfall during the COVID-19 pandemic as most of the economic activities were halted during Q1 and Q2 2020. Moreover, timings related to visiting of hospital and therapies for the patients were also interrupted that had resulted in a delay of treatment due to the COVID-19 Pandemic.

The global non-small cell lung cancer market is segmented based on type, therapy, diagnosis, and end-user. Based on the type segment, the market is segmented into adenocarcinomas, squamous cell carcinoma, large cell carcinomas, and others. Based on the therapy segment, the market is segmented into chemotherapy, targeted therapy, radiation therapy, surgery, cryosurgery, and others. Among these, the chemotherapy segment is anticipated to have significantly large shares during the forecast period. Based on the diagnosis segment, the market is segmented into CT scan, x-rays, sputum cytology, bronchoscopy, laboratory tests, thoracoscopy, and others. Further based on the end-user segment, the market is bifurcated into multispecialty hospitals and cancer research centers

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is expected to have the fastest-growing region in the market. Growing healthcare infrastructure which was once a stronghold of the US and a few European economies such as France, Italy, and Germany, is set to expand to emerging economies, to be planned predominantly in the Asia-Pacific region. The growing geriatric population in the Asian economies of Japan, South Korea, Taiwan, and China, which are susceptible to cancer, is set to increase the demand for diagnosis and treatment.

Further, Eli Lilly and Co., Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck &Co., Inc., AstraZeneca PLC among others are the key players in the market, which are adopting different strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, among others. For instance, in May 2020, AstraZeneca PLC and Daiichi Sankyo Co., ltd. had received Breakthrough Therapy designation from US FDA for the treatment of patients suffering from metastatic non-small cell lung cancer (NSCLC).

Research Methodology

The market study of the global non-small cell lung cancer market is incorporated by extensive primary and secondary research conducted by the research team at OMR Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market

Whitepapers, research papers, and news blogs

Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Non-Small Cell Lung Cancer Market Research And Analysis By Type

Global Non-Small Cell Lung Cancer Market Research And Analysis By Therapy

Global Non-Small Cell Lung Cancer Market Research And Analysis By Diagnosis

Global Non-Small Cell Lung Cancer Market Research And Analysis By End-User

The Report Covers

Comprehensive research methodology of the global non-small cell lung cancer market

This report also includes a detailed and extensive market overview with key analyst insights

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations

Analysis of regional regulations and other government policies impacting the global non-small cell lung cancer market

Insights about market determinants that are stimulating the global non-small cell lung cancer market

Detailed and extensive market segments with the regional distribution of forecasted revenues

Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market Industry
  • Recovery Scenario of Global Non-Small Cell Lung Cancer Market Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Non-Small Cell Lung Cancer Market By Type
    • 5.1.1. Adenocarcinomas
    • 5.1.2. Squamous Cell Carcinoma
    • 5.1.3. Large Cell Carcinomas
    • 5.1.4. Others
  • 5.2. Global Non-Small Cell Lung Cancer Market By Therapy
    • 5.2.1. Chemotherapy
    • 5.2.2. Targeted Therapy
    • 5.2.3. Radiation Therapy
    • 5.2.4. Surgery
    • 5.2.5. Cryosurgery
    • 5.2.6. Others
  • 5.3. Global Non-Small Cell Lung Cancer Market By Diagnosis
    • 5.3.1. CT Scan
    • 5.3.2. X-Rays
    • 5.3.3. Sputum Cytology
    • 5.3.4. Bronchoscopy
    • 5.3.5. Laboratory Tests
    • 5.3.6. Thoracoscopy
    • 5.3.7. Others
  • 5.4. Global Non-Small Cell Lung Cancer Diagnosis And Therapeutics Market By End-User
    • 5.4.1. Multispeciality Hospitals
    • 5.4.2. Cancer Research Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Agena Bioscience, Inc.
  • 7.3. Arqule Inc.
  • 7.4. Amgen Inc.
  • 7.5. AstraZeneca PLC
  • 7.6. Bayer AG
  • 7.7. Biodesix, Inc.
  • 7.8. Boehringer Ingelheim International GmbH
  • 7.9. Bristol Myers Squibb Co.
  • 7.10. DAIICHI SANKYO CO. LTD.
  • 7.11. Eli Lilly and Co.
  • 7.12. Exosome Diagnostics Corp.
  • 7.13. F. Hoffman-La Roche, Inc.
  • 7.14. Genentech, Inc.
  • 7.15. GlaxoSmithKline PLC
  • 7.16. Illumina, Inc.
  • 7.17. Merck & Co., Inc.
  • 7.18. Novartis International Ag
  • 7.19. Personal Genome Diagnostics Inc.
  • 7.20. Pfizer Inc.
  • 7.21. Qiagen NV
  • 7.22. Sanofi SA
  • 7.23. SAGA Diagnostics AB
  • 7.24. Thermo Fisher Scientific Inc.

LIST OF TABLES

  • 1. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBAL ADENOCARCINOMAS NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL SQUAMOUS CELL CARCINOMA NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL LARGE CELL CARCINOMAS NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL OTHERS NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 8. GLOBAL CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL RADIATION THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL SURGERY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL CRYOSURGERY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL OTHERS THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 15. GLOBAL CT SCAN INNON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL X-RAYS IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBAL BRONCHOSCOPY IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL LABORATORY TESTS IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL THORACOSCOPY IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 21. GLOBAL OTHERS DIAGNOSIS IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 22. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 23. GLOBAL NON-SMALL CELL LUNG CANCER IN MULTISPECIALTY HOSPITALSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 24. GLOBAL NON-SMALL CELL LUNG CANCER IN CANCER RESEARCH CENTERSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 25. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 26. NORTH AMERICAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 27. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 28. NORTH AMERICAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 29. NORTH AMERICAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 30. NORTH AMERICAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 31. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 32. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 33. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 34. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 35. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 36. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 37. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 38. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 39. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 40. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 41. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 42. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 43. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 44. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL NON-SMALL CELL LUNG CANCER MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL NON-SMALL CELL LUNG CANCER MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL NON-SMALL CELL LUNG CANCER MARKET, 2020-2027 (%)
  • 4. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY THERAPY, 2020 VS 2027 (%)
  • 6. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 7. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY END-USER, 2020 VS 2027 (%)
  • 8. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL ADENOCARCINOMAS NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 10. GLOBAL SQUAMOUS CELL CARCINOMA NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 11. GLOBAL LARGE CELL CARCINOMAS NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 12. GLOBAL OTHERS NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 13. GLOBAL CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 14. GLOBAL TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 15. GLOBAL RADIATION THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 16. GLOBAL SURGERY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 17. GLOBAL CRYOSURGERY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 18. GLOBAL OTHERS THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 19. GLOBAL CT SCAN IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 20. GLOBAL X-RAYS IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 21. GLOBAL SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 22. GLOBAL BRONCHOSCOPY IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 23. GLOBAL LABORATORY TESTS IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 24. GLOBAL THORACOSCOPY IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 25. GLOBAL OTHERS DIAGNOSIS IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 26. GLOBAL NON-SMALL CELL LUNG CANCER IN MULTISPECIALTY HOSPITALSMARKET SHARE, 2020 VS 2027 (%)
  • 27. GLOBAL NON-SMALL CELL LUNG CANCER IN CANCER RESEARCH CENTERSMARKET SHARE, 2020 VS 2027 (%)
  • 28. US NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. CANADA NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. UK NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. FRANCE NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. GERMANY NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. ITALY NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. SPAIN NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. ROE NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 36. INDIA NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 37. CHINA NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 38. JAPAN NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 39. SOUTH KOREA NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 40. REST OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 41. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)